Tumour vaccine approaches for CNS malignancies: Progress to date

Drugs

Volumn 69, Issue 3, 2009, Pages 241-249

  Ebben, Johnathan D ^a   Rocque, Brandon G ^a   Kuo, John S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; HERPES SIMPLEX VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; RECOMBINANT INTERLEUKIN 12; TEMOZOLOMIDE; UNCLASSIFIED DRUG; WILMS TUMOR 1 PEPTIDE;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DENDRITIC CELL; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NEPHROBLASTOMA; NONHUMAN; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; VACCINES, SUBUNIT;

EID: 62149102209     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969030-00001     Document Type: Review

References (43)

1. Kindt TJ, Goldsby RA, Osborne BA. Kuby immunology. 6th ed. New York: W.H. Freeman and Company, 2007
2. Yamanaka R, Itoh K. Peptide-based immunotherapeutic approaches to glioma: a review. Expert Opin Biol Ther 2007 May; 7 (5): 645-9
3. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007 Jun 1; 25 (16): 2288-94
4. Sampson JH, Archer GE, Mitchell DA, et al. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008 Oct; 20 (5): 267-75
5. M.D. Anderson Cancer Center. An immunotherapy vaccine against grade IV brain tumors [ClinicalTrials.gov identifier NCT00090597]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2009 Feb 10]
6. Ochiai H, Archer GE, Herndon JE, et al. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother 2008 Jan; 57 (1): 115-21
7. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008 May; 108 (5): 963-71
8. Okada H, Low KL, Kohanbash G, et al. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 2008 Jul; 88 (3): 245-50
9. Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006 Oct; 97 (10): 970-6
10. Yajima N, Yamanaka R, Mine T, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005 Aug 15; 11 (16): 5900-11
11. Okaji Y, Tsuno NH, Tanaka M, et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer 2008 Feb; 44 (3): 383-90
12. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008 May; 14 (10): 3098-104
13. Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 2007 Dec; 5: 10
14. Walker DG, Laherty R, Tomlinson FH, et al. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 2008 Feb; 15 (2): 114-21
15. Ishikawa E, Tsuboi K, Yamamoto T, et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 2007 Aug; 98 (8): 1226-33
16. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005 Aug 1; 11 (15): 5515-25
17. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005 Jun 1; 11 (11): 4160-7
18. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004 Nov-Dec; 27 (6): 452-9
19. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004 Nov; 22 (21): 4272-81
20. Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 2004 Jul; 6 (3): 236-46
21. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004 Jul 15; 64 (14): 4973-9
22. Schneider T, Gerhards R, Kirches E, et al. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 2001; 53 (1): 39-46
23. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 Mar 19; 392 (6673): 245-52
24. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001 Nov; 94 (4): 459-73
25. Koido S, Ohana M, Liu C, et al. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin Immunol 2004 Dec; 113 (3): 261-9
26. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001 Sep; 50 (7): 337-44
27. Liu GT, Black KL, Yu JS. Sensitization ofmalignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 2006 Apr; 5 (2): 233-47
28. Liu G, Akasaki Y, Khong HT, et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 2005 Aug 4; 24 (33): 5226-34
29. Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 2003 Aug 15; 9 (9): 3294-302
30. Iizuka Y, Kojima H, Kobata T, et al. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. Int J Cancer 2006 Feb 15; 118 (4): 942-9
31. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008 Feb; 10 (1): 10-8
32. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 2008 Jul 31, 2008; 359 (5): 539-51
33. Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today 1998 Nov; 4 (11): 478-84
34. Li Z. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin Immunol 1997 Oct; 9 (5): 315-22
35. Hoos A, Levey DL, Lewis JJ. Autologous heat shock protein-peptide complexes for vaccination against cancer: from bench to bedside. Dev Biol (Basel) 2004; 116: 109-15
36. Amato RJ. Heat-shock protein-peptide complex-96 for the treatment of cancer. Expert Opin Biol Ther 2007 Aug; 7 (8): 1267-73
37. Qiao Y, Liu B, Li Z. Activation of NK cells by extracellular heat shock protein 70 through induction of NKG2D ligands on dendritic cells. Cancer Immun 2008; 8: 12
38. Facoetti A, Nano R, Zelini P, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005 Dec; 11 (23): 8304-11
39. Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 2003 Oct; 13 (5): 343-51
40. Seliger B, Cabrera T, Garrido F, et al. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002 Feb; 12 (1): 3-13
41. Aptsiauri N, Cabrera T, Mendez R, et al. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007; 601: 123-31
42. Castriconi R, Dondero A, Negri F, et al. Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur J Immunol 2007 Nov; 37 (11): 3190-6
43. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006 Mar 15; 66 (6): 3294-302